Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study
Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study
复制标题
DOI：
10.1111/jdv.13230
复制
发表时间：
2015-12-01
影响因子：
9.2
通讯作者：
Vink, J.
中科院分区：
文献类型：
--
作者：
Lambert, J.;Hol, C. W.;Vink, J.
背景局部治疗是寻常型银屑病的主要治疗方法。卡泊三醇（Cal）50 μ g/g+倍他米松0.5 mg/g（以二丙酸盐计; BD）的固定组合是一线局部治疗，可作为凝胶或软膏使用。在PRO-long（一项长期非干预性研究）中比较了这些固定复方制剂的使用，目的描述和比较患者对固定组合凝胶和软膏制剂的看法;包括疗效、依从性行为、治疗满意度和健康相关的生活质量（HRQoL）方面在长期的现实生活银屑病管理。方法PRO-long是一个多中心，前瞻性，观察性，在临床实践中处方固定复方Cal/BD凝胶或软膏的患者的52周研究。对于最终分析，在第24、36和52周评估了以下内容：根据患者对疾病严重程度、依从行为治疗满意度（9项药物治疗满意度问卷）和HRQoL结果328例患者接受每日1次Cal/BD凝胶（n = 152）或软膏（n = 176）。第52周时，报告银屑病严重程度为“轻度"/”极轻度“的患者比例高于基线（凝胶：60. 2 vs. 47. 1%;软膏：58. 8 vs. 42. 4%），使用凝胶的患者报告的治疗满意度高于使用软膏的患者。与软膏相比，更高比例的患者发现凝胶“易于”使用（66.7%对45.2%）。每日应用的治疗需要
Background Topical therapies are the mainstay of treatment for psoriasis vulgaris. The fixed combination of calcipotriol (Cal) 50 mu g/g plus betamethasone 0.5 mg/g (as dipropionate; BD) is a first-line topical treatment and available as a gel or ointment. The use of these fixed combination products was compared in PRO-long, a long-term noninterventional study, for which interim results (4 and 12 weeks) have previously been reported.Objective To describe and compare patients' perspectives on the fixed combination gel and ointment formulations; to include efficacy, adherence behaviour, treatment satisfaction and health-related quality of life (HRQoL) aspects during long-term real-life psoriasis management.Methods PRO-long was a multicentre, prospective, observational, 52-week study of patients prescribed fixed combination Cal/BD gel or ointment in clinical practice. For final analysis the following were assessed at weeks 24, 36 and 52: differences in the proportion of patients with 'mild'/'very mild' disease according to patient's global assessment of disease severity, adherence behaviour, treatment satisfaction (nine-item treatment satisfaction questionnaire for medication) and HRQoL (Skindex-29).Results Patients (n = 328) were prescribed once-daily Cal/BD gel (n = 152) or ointment (n = 176). At week 52, a higher proportion of patients reported that the severity of their psoriasis was 'mild'/'very mild' vs. baseline (gel: 60.2 vs. 47.1%; ointment: 58.8 vs. 42.4%), with greater treatment satisfaction reported in patients using gel vs. those using ointment. A higher proportion of patients found the gel 'easy' to use compared with the ointment (66.7 vs. 45.2%). Daily application of treatment took